RNAi Therapeutics
•24 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
RNAi therapeutics are part of Lilly's genetic medicine push.
|
$985.74B |
$1063.02
+2.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 siRNA program represents RNA interference therapeutics in Regeneron’s genetic medicines portfolio.
|
$80.89B |
$772.67
+1.24%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$52.15B |
$408.34
+2.64%
|
|
RNA
Avidity Biosciences, Inc.
RNA interference (siRNA) payloads are part of the therapeutic approach described (AOC delivering RNA-based payloads).
|
$9.27B |
$72.20
+0.18%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$8.83B |
$71.16
+11.40%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an RNA interference therapeutic, aligning with the RNAi Therapeutics category.
|
$5.02B |
$58.25
+5.62%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLJ? APL-3007 is an siRNA therapeutic targeting FcRn, placing the program under the RNAi Therapeutics theme.
|
$3.14B |
$23.76
-4.46%
|
|
WVE
Wave Life Sciences Ltd.
WVE-007 includes an siRNA (RNA interference) program, making RNAi therapeutics a core modality for the company.
|
$2.39B |
$15.46
+3.07%
|
|
SRPT
Sarepta Therapeutics, Inc.
siRNA platform (TRiM) with Arrowhead collaboration positions Sarepta in RNA interference therapeutics.
|
$2.06B |
$21.80
+3.46%
|
|
AGIO
Agios Pharmaceuticals, Inc.
AG-236 is an siRNA (RNAi) therapeutic in preclinical development, fitting RNAi therapeutics as a major modality in Agios's pipeline.
|
$1.59B |
$27.30
-0.53%
|
|
QURE
uniQure N.V.
miQURE silencing technology enables RNA interference-based therapeutics, placing the company in the RNAi therapeutics modality.
|
$1.24B |
$22.52
-0.49%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
VIR
Vir Biotechnology, Inc.
Elebsiran is an RNA interference (RNAi) therapeutic, placing Vir in RNAi Therapeutics.
|
$804.33M |
$5.97
+3.20%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's RNA interference modality (RNAi therapeutics) aligns with a gene-silencing oligonucleotide approach described in the program.
|
$340.93M |
$7.16
-1.99%
|
|
BNTC
Benitec Biopharma Inc.
Benitec's ddRNAi approach centers on RNA interference therapeutics, placing it under RNAi Therapeutics.
|
$312.12M |
$11.77
-1.01%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$279.70M |
$5.80
-2.19%
|
|
VYGR
Voyager Therapeutics, Inc.
VY1706 uses siRNA payload delivered via TRACER capsids, mapping to RNAi Therapeutics.
|
$226.31M |
$4.00
-1.96%
|
|
ALEC
Alector, Inc.
ADP064-ABC includes an anti-tau siRNA program, representing RNA interference therapeutics.
|
$161.94M |
$1.67
+4.37%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$147.14M |
$1.71
+4.60%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$36.37M |
$5.37
-0.56%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT is described as a precision antisense therapy, aligning with RNAi therapeutics.
|
$14.05M |
$1.03
-2.36%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.70M |
$1.12
-3.85%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$6.09M |
$6.91
-5.47%
|
|
RGBP
Regen BioPharma, Inc.
DiffronC is described as an in vivo siRNA therapy, placing RGBP in the RNAi Therapeutics space.
|
$224038 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
